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Virus-specific T-cell immune responses are important in restraint of human immunodeficiency virus type 1
(HIV-1) replication and control of disease. Plasma viral load is a key determinant of disease progression and
infectiousness in HIV infection. Although HIV-1 subtype C (HIV-1C) is the predominant virus in the AIDS
epidemic worldwide, the relationship between HIV-1C-specific T-cell immune responses and plasma viral load
has not been elucidated. In the present study we address (i) the association between the level of plasma viral
load and virus-specific immune responses to different HIV-1C proteins and their subregions and (ii) the
specifics of correlation between plasma viral load and T-cell responses within the major histocompatibility
complex (MHC) class I HLA supertypes. Virus-specific immune responses in the natural course of HIV-1C
infection were analyzed in the gamma interferon (IFN-)-enzyme-linked immunospot assay by using synthetic
overlapping peptides corresponding to the HIV-1C consensus sequence. For Gag p24, a correlation was seen
between better T-cell responses and lower plasma viral load. For Nef, an opposite trend was observed where
a higher T-cell response was more likely to be associated with a higher viral load. At the level of the HLA
supertypes, a lower viral load was associated with higher T-cell responses to Gag p24 within the HLA A2, A24,
B27, and B58 supertypes, in contrast to the absence of such a correlation within the HLA B44 supertype. The
present study demonstrated differential correlations (or trends to correlation) in various HIV-1C proteins,
suggesting (i) an important role of the HIV-1C Gag p24-specific immune responses in control of viremia and
(ii) more rapid viral escape from immune responses to Nef with no restraint of plasma viral load. Correlations
between the level of IFN--secreting T cells and viral load within the MHC class I HLA supertypes should be
considered in HIV vaccine design and efficacy trials.
An essential role for virus-specific CD8-T-cell responses in
the control of simian immunodeficiency virus (SIV) and hu-
man immunodeficiency virus (HIV) infection has been docu-
mented (29, 34, 61, 70). Potent cytotoxic-T-lymphocyte (CTL)
responses can apparently cause a dramatic drop of plasma viral
load in acute HIV type 1 (HIV-1) infection (7, 38) and contain
viral replication (54). The emergence of HIV-1-specific CTLs
in acute infection coincides with a plasma viral load decline (7,
38). The presence of CD8 T cells was directly correlated with
the control of SIV infection in the macaque model (29, 61).
Moreover, vaccine-induced CTL responses protected ma-
caques against the development of AIDS (1, 3, 4, 64). Taken
together, these data provide evidence for a protective role of
virus-specific CD8-T-cell responses. However, taken alone,
CTL responses are unable in most cases to prevent HIV-1
infection or thwart viral escape from immune recognition (8,
25, 58), which necessitates a cooperation with CD4-T-helper
responses and neutralizing antibodies. An additional challenge
for efficient CTL responses is the accumulating genetic diver-
sity of HIV-1 in the global AIDS epidemic driven by a rela-
tively high evolution rate of the virus (18, 36). HIV-1 subtype
C (HIV-1C) is the most prevalent HIV-1 subtype worldwide
(15, 55) and is responsible for the majority of new HIV-1
infections (16, 55). The emergent ascendancy of HIV-1C indi-
cates a need for a comprehensive analysis of HIV-1C-specific
immune responses, both CD4 and CD8, in the context of
vaccine design.
The association between CTL responses and plasma viral
load has been addressed in previous studies of HIV-1B infec-
tion (10, 27, 34, 59). An inverse correlation between virus-
specific CTL responses and plasma viral load was observed for
Gag (14, 53), Pol (6, 53), and Env (47). In contrast, an asso-
ciation with high viral load was reported for Env- and Nef- (5),
Gag-, Pol-, and Nef-specific CTL responses (39) or for the total
frequency of CD8 T cells (5). No significant correlation be-
tween CTL responses and plasma viral load was found in a
number of other recent studies (13, 14, 19, 42). A correlation
between CTL responses and higher HIV production was ob-
served during highly active antiretroviral therapy, but an in-
verse correlation was seen at rapid virus rebound (44) or in
patients with relatively high CD4 counts (37). The discrep-
ancies in correlation between plasma viral load and virus-spe-
cific T-cell immune responses might be explained, at least in
part, by differences in assay methodologies, the targeting of
different epitopes across the viral genome, different disease
stages, and differences between diverse population groups.
Discrepancies have also been reported between CD8-T-cell
responses as assayed by tetramer staining and immune func-
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tion indicators such as gamma interferon (IFN-) release (21,
26, 37).
The major histocompatibility complex (MHC) class I HLA
alleles are involved in presenting foreign antigens to immune
cells and are believed to be essential in host immune responses
to viral infections. Some HLA alleles or haplotypes have been
associated with altered HIV-1 susceptibility and/or progression
to AIDS (9, 11, 12, 28, 31, 40, 60, 65–67). The B*35-Cw*04
haplotype was linked with rapid progression of HIV infection.
In contrast, B*27 and B*57 were shown to have a protective
effect on progression to AIDS (25, 43, 56). HLA-A29 and
HLA-B22 were associated with rapid progression, whereas B14
and C8 were associated with slow progression. (28) Different
levels of plasma viral load in HIV-1C infection were associated
with several HLA class I alleles and haplotypes (66), suggesting
favorable (B*57) and unfavorable (B*39, A*30-Cw*03, *02-
Cw*16, A*23-B*14, and A*23-Cw*07) HLA alleles. Differ-
ences in frequencies of MHC class I HLA alleles within pop-
ulations might be one of the reasons for disagreements
between different studies that addressed associations between
CTL responses and plasma viral load. An introduction of ma-
jor HLA class I supertypes (62, 63) that grouped the MHC
class I alleles on the basis of their functional properties allowed
us to address associations between CTL responses and plasma
viral load within the HLA supertypes.
In the present study, we addressed associations between
virus-specific T-cell immune responses and plasma viral load in
the course of natural HIV-1C infection in Botswana, an Afri-
can country with a severe burden of HIV-1C infection. The
virus-specific immune responses were measured in asymptom-
atic HIV-1-infected blood donors by using overlapping pep-
tides that spanned HIV-1C proteins in the IFN-–enzyme-
linked immunospot (ELISPOT) assay. Correlations between
T-cell immune responses and plasma viral loads were esti-
mated for each HIV-1C protein and subregions of the struc-
tural proteins Gag (p17, p24, and p2p7p1p6), Pol (protease,
reverse transcriptase, RNase H, and integrase), and Env
(gp120 and gp41) by analysis of unadjusted and adjusted (for
the CD4 and CD8 counts) sets of data. Correlation was also
assessed within five major HLA supertypes that were most
common among the study population.
MATERIALS AND METHODS
Study subjects. The sample set used in the present study was the same col-
lection from asymptomatic donors who tested HIV seropositive at the National
Blood Transfusion Centre in Gaborone, Botswana, as described previously (48,
50). Details on the HIV testing, sample collection, peripheral blood mononu-
clear cell (PBMC) isolation, and relevant information of the cohort were de-
scribed previously (48, 50). The total number of study subjects was 105. Plasma
viral load data was available for 103 subjects (median, 37,769 copies/ml; range,
400 to 750,000 copies/ml). CD4 (median count, 434; mean count, 451) and
CD8 (median count, 984; mean count, 1,006) data were available for 98 study
subjects. Plasma viral load determinations, CD4 and CD8 counts, and HLA
typing were performed as described previously (48, 50).
Synthetic peptides. PBMCs were screened for T-cell immune responses in the
IFN-–ELISPOT assay within HIV-1C Gag, Pol, Vif, Vpr, Tat, Rev, Vpu, Env,
and Nef by using overlapping peptides of 15 to 20 amino acids that overlapped
by 10 amino acids based on the HIV-1C consensus sequence as described pre-
viously (48, 50). Peptides spanning variable regions were represented by two or
three peptides that represented major viral variants based on our previous study
of HIV-1C consensus sequence (51). The purity of peptides in most cases was
85%.
ELISPOT assay. HIV-1C-specific T-cell responses were measured by quanti-
fication of the IFN- release in a screening ELISPOT assay as described previ-
ously (48, 50). The anti-IFN- monoclonal antibody (MAb) 1-D1K (Mabtech
AB, Nacka, Sweden), biotinylated anti-IFN- MAb 7-B6-1 (Mabtech AB), and
streptavidin-alkaline phosphatase conjugate (Mabtech AB) were used. IFN--
producing cells were counted by direct visualization or by using a stereo micro-
scope and expressed as spot-forming cells per million PBMCs. Only responses
with a magnitude 100 spot-forming cells/million PBMC were considered pos-
itive in all screening tests. Immune responses to a particular viral protein were
expressed as a sum of IFN-–ELISPOT T-cell responses to individual peptides
spanning the protein. The overall CD8-T-cell specificity of the IFN-–ELIS-
POT-based responses to synthetic peptides was demonstrated previously by
others (23, 24) and by us (48, 50) in a series of CD8 and CD4 depletion and
enrichment experiments. However, the CD4 or CD8 origin of responses was
not systematically quantified in the present study, and therefore the immune
responses are presented as total T-cell immune responses.
Statistical analysis. Statistical analyses and basic graphical delineations were
performed by using SigmaPlot 2001 (SPSS, Inc.), Splus v.6.0 (Insightful Corp.),
and Microsoft Excel 2000 (Microsoft Corp.) enhanced by the package Analyze-It
(Analyze-It Software, Ltd.). For unadjusted analyses, the linear correlation
(slope) between the log plasma viral load and the HIV-1C-specific T-cell re-
sponse within each viral protein or protein subregion was assessed by using the
Spearman rank correlation coefficient. Correlations adjusted for CD4 and CD8
counts were assessed by using linear regression models. Spearman rank corre-
lation coefficients were used to compare the log plasma viral load and the
HIV-1C-specific immune response within each of the five major HLA super-
types. Linear regression models were used to test whether there were interac-
tions between HLA supertypes and T-cell responses in their affect on the log
plasma viral load. All tests were two-tailed, and P values of 0.05 indicated
statistical significance. No adjustments for multiple comparisons were made.
RESULTS
T-cell responses to HIV-1C proteins. The association be-
tween virus-specific T-cell responses and plasma viral load for
the HIV-1C Gag, Pol, Vif, Vpr, Tat, Rev, Vpu, Env, and Nef
proteins was analyzed (Fig. 1). The opposite trends were re-
vealed in the correlation between T-cell immune responses
and viral load for the Gag and Nef proteins (Table 1). Increas-
ing values for HIV-1C Gag-specific T-cell responses were cor-
related with decreasing levels of plasma viral load (P  0.020,
slope  0.31, and 95% confidence interval [CI]  0.52 to
0.05 in the unadjusted analysis [unadjusted], and P  0.025,
slope  0.27, and 95% CI  0.51 to 0.04 in the adjusted
analysis [adjusted]). In contrast, higher HIV-1C Nef-specific
T-cell responses were correlated with higher plasma viral load,
although in the unadjusted analysis only a trend was observed
(P  0.079, slope  0.24, and 95% CI  0.03 to 0.48 [unad-
justed], and P 0.049, slope 0.38, and 95% CI 0.00 to 0.75
[adjusted]). No statistically significant correlation between T-
cell immune responses and plasma viral load was found for
other HIV-1C proteins or for total T-cell responses in either
the unadjusted analysis or the adjusted analysis (Fig. 1 and
Table 1).
Association between T-cell responses and viral load within
the Gag, Pol, and Env. To address potential trends within the
structural HIV-1C proteins, a similar analysis of association
between the HIV-1C-specific T-cell responses and plasma viral
load was performed for the p17, p24, and p2/p7/p1/p6 cleavage
products of Gag; the protease, reverse transcriptase, RNase H,
and integrase of Pol; and the gp120 and gp41 of Env (Fig. 2,
accompanied by Table 2). Only Gag p24 demonstrated a strong
inverse correlation between T-cell response and viral load (P
0.0016, slope  0.40, and 95% CI  0.60 to 0.16 [unad-
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justed], and P 0.005, slope0.43, and 95% CI0.72 to
0.14 [adjusted]).
For both HIV-1C proteins and their subregions, unadjusted
and adjusted analyses resulted in similar associations and/or
trends (Fig. 1 and 2, Tables 1 and 2).
T-cell responses and viral load in relation to MHC class I
supertypes. Previously, we identified HLA class I alleles and/or
antigen specificities that are most common in the Botswana
population (49, 50). This allowed us to determine how HLA
alleles common in Botswana are represented within the major
HLA class I supertypes (62, 63). The distribution of the Bo-
tswana HLA alleles within MHC class I supertypes highlighted
specifics of the common HLA alleles in the Botswana popula-
tion (Table 3). Based on a cumulative allele frequency, the A24
supertype included the HLA alleles that were most common in
Botswana (the cumulative frequency of A23 and A30 antigen
specificities was 37.2%), followed by the A2, B27, B44, and B58
supertypes that were accountable for a frequency of about 20%
each in the Botswana population. However, four HLA class I
supertypes—A1, A3, B7, and B62—included HLA alleles that
were seen at a relatively low frequency in Botswana (cumula-
tive frequency of 20%). Based on this analysis, we selected
five of the most representative major HLA class I supertypes in
Botswana, namely, A2, A24, B27, B44, and B58, and analyzed
associations and trends between HIV-1C-specific T-cell re-
sponses and plasma viral load within these HLA supertypes.
About 97.8% of the study population was covered by at least
one HLA allele belonging to the A2, A24, B27, B44, or B58
HLA supertypes.
Distinct patterns of correlation were found within different
FIG. 1. Association between HIV-1C-specific T-cell responses and plasma viral load. Regression curves represent results of unadjusted and
adjusted analyses. Corresponding statistics are shown in Table 1.
TABLE 1. Association between HIV-1C-specific T-cell responses
and plasma viral load
Protein
Unadjusted analysis (Spearman
rank correlation coefficient)
Adjusted analysis
(linear regression)
Slope
estimate 95% CI
a P Slopeestimate 95% CI
a P
Gag 0.31 0.52, 0.05 0.020 0.27 0.51, 0.04 0.025
Pol 0.01 0.25, 0.22 0.90 0.12 0.21, 0.45 0.47
Vif 0.10 0.36, 0.18 0.47 0.58 1.57, 0.41 0.24
Vpr 0.20 0.45, 0.07 0.15 0.39 1.90, 1.11 0.60
Tat 0.02 0.24, 0.29 0.86 0.15 0.88, 0.58 0.68
Rev 0.05 0.31, 0.23 0.75 0.25 0.96, 0.45 0.47
Vpu 0.04 0.30, 0.22 0.76 0.49 1.77, 2.75 0.66
Env 0.01 0.29, 0.31 0.94 0.04 0.39, 0.48 0.85
Nef 0.24 0.03, 0.48 0.079 0.38 0.00, 0.75 0.049
HIV-1C 0.16 0.35, 0.03 0.11 0.04 0.15, 0.07 0.45
a Minimum, maximum.
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MHC class I HLA supertypes (Fig. 3). The correlation patterns
also differed across the HIV-1C proteins. Pronounced HLA
supertype-based differences were seen in the HIV-1C Gag and
Gag p24. Within HIV-1C Gag, a statistically significant corre-
lation between strong T-cell responses and low viral load was
found in the A2 supertype (P  0.0058, slope  0.53, and
95% CI  0.76 to 0.17 [unadjusted], and P  0.0024, slope
 0.53, and 95% CI  0.87 to 0.19 [adjusted]). The A24,
B27, and B58 supertypes demonstrated trends toward the same
correlation in both unadjusted and adjusted analyses (P 
0.065, 0.059, and 0.066, respectively, in the adjusted analysis).
Interestingly, there was no correlation within the B44 super-
type (P  0.95). The observed associations for Gag were more
pronounced for HIV-1C Gag p24, revealing a significant cor-
relation between higher T-cell responses and lower plasma
viral loads for all but the B44 supertype (P  0.0028 for A2, P
 0.0086 for A24, P 0.0142 for B27, and P 0.0144 for B58,
but P  0.84 for B44 [unadjusted]; P  0.0009 for A2, P 
0.0053 for A24, P  0.0073 for B27, P  0.0064 for B58, but P
 0.81 for B44 [adjusted]).
FIG. 2. Association between HIV-1C-specific T-cell responses and plasma viral load in subregions of Gag, Pol, and Env proteins. Regression
curves represent results of unadjusted and adjusted analyses. Corresponding statistics are shown in Table 2.
TABLE 2. Association between HIV-1C-specific T-cell responses and plasma viral load within the structural HIV-1C proteins
Protein
Unadjusted analysis
(Spearman rank correlation coefficient) Adjusted analysis (linear regression)
Slope estimate 95% CIa P Slope estimate 95% CIa P
Gag p17 0.02 0.24, 0.27 0.90 0.43 1.32, 0.46 0.34
Gag p24 0.40 0.60, 0.16 0.0016 0.43 0.72, 0.14 0.005
Gag p2/p7/p1/p6 0.12 0.14, 0.37 0.35 0.33 0.44, 1.11 0.39
Pol protease 0.05 0.30, 0.22 0.73 0.26 1.15, 1.67 0.71
Pol reverse transcriptase 0.01 0.28, 0.26 0.96 0.37 0.07, 0.81 0.10
Pol RNase H 0.11 0.14, 0.35 0.40 0.90 1.06, 2.86 0.35
Pol integrase 0.02 0.23, 0.27 0.86 0.00 0.78, 0.78 0.90
Env gp120 0.00 0.25, 0.26 0.97 0.31 0.43, 1.05 0.40
Env gp41 0.15 0.41, 0.13 0.28 0.12 0.72, 0.48 0.69
a Minimum, maximum.
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If T-cell responses and viral load correlate inversely for
some HLA supertypes but not for others, then T-cell responses
may be HLA supertype specific. To assess this question statis-
tically for HIV-1C Gag and for Gag p24, we used linear re-
gression models to test whether HLA supertype and T-cell
responses interacted in their effect on viral load. To test a
potential interaction between HLA supertype and T-cell re-
sponses, we used linear regression models for the HIV-1C Gag
and Gag p24 subregion. Two trends were found: (i) for Gag
(HLA supertype A2 versus B44) there was a strong negative
correlation for A2 but no correlation for B44 supertype, with
an interaction test P value of 0.086; (ii) for Gag p24 (HLA
supertype A2 versus B44) there was also a strong negative
correlation for A2 but no correlation for B44 supertype, with
an interaction test P value of 0.063. The strength of the ob-
served correlation between the MHC class I HLA supertypes
and the plasma viral load could be clarified by increasing the
sample size in each HLA supertype.
Within the A24 supertype, higher Nef-specific responses
were correlated with higher plasma viral load (P 0.011, slope
 0.45, 95% CI  0.12 to 0.69 [unadjusted], and P  0.006,
slope  0.45, and 95% CI  0.13 to 0.77 [adjusted] [Fig. 4]).
Trends for a correlation between higher virus-specific re-
sponses and lower viral load within the A24 supertype were
seen for gp41 (P 0.070, slope0.35, and 95% CI0.65
to 0.03 [unadjusted], and P  0.091, slope  0.32, and 95%
CI  0.69 to 0.05 [adjusted]), and the total HIV-1C (P 
0.077, slope  0.23, and 95% CI  0.46 to 0.03 [unadjust-
ed], and P  0.071, slope  0.23, and 95% CI  0.49 to
0.02 [adjusted]).
No other significant correlations were found between HIV-
1C-specific T-cell responses and viral load.
DISCUSSION
In the present study correlation patterns between virus-spe-
cific immune responses and plasma viral load were found to
vary at two different levels: viral and host. Specifically, differ-
ences in correlation were detected (i) between the viral pro-
teins and (ii) between different MHC class I HLA supertypes.
Although the results of the present study warrant further re-
search in regards to different stages of disease (i.e., acute
versus chronic), these findings have direct relevance for our
understanding of HIV pathogenesis, as well as for the design of
HIV vaccines and vaccine efficacy trials.
HIV-1C dominates in the global AIDS epidemic. However,
associations between HIV-1C-specific immune responses and
viral loads have not been analyzed previously. In addition,
differences in geographical distribution of HLA alleles, taken
in the context of MHC class I restriction of CTL epitope
presentation, may imply another level of divergence between
populations and/or ethnic groups. For example, the predomi-
nance of HIV-1C in southern Africa (15, 16, 51, 52, 68, 69) and
specifics of MHC class I HLA allele frequencies in the Bo-
tswana population (49, 50) determined a unique immunodom-
inant profile of cell-mediated immune responses (48, 50).
Patterns of correlation between HIV-1C-specific immune
responses and plasma viral load for different viral proteins
included an association between strong T-cell responses and
lower viremia or an association between stronger T-cell re-
sponses and high viral load. In most instances the magnitude of
T-cell response was not correlated with either a higher or a
lower viral load. A correlation between stronger T-cell re-
sponses and lower plasma viral load in the Gag/Gag-p24 pro-
teins coexisted with a trend toward an opposite correlation in
the Nef, whereas there was no pattern of correlation between
T-cell responses and plasma viral load for the other HIV-1C
proteins (analyzed for the entire study group).
The correlation between virus-specific immune responses
and plasma viral load in HIV-1C Gag, and particularly in Gag
p24, suggests an important role of p24-specific T-cell responses
in the control of viremia. The highly conserved p24 appears to
have functional constraints and may not be flexible for accu-
mulation of new mutations, which in turn would allow control
of the virus by a capable Gag p24-specific T-cell response. It
also raises the notion of relative importance of HIV proteins
for vaccine design and suggests that the Gag p24 might be the
most attractive region to include in vaccine candidates to in-
duce T-cell immune responses that could contain viremia.
In contrast, the correlation (or trend) between increasing
Nef-specific T-cell responses and increasing plasma viral load
suggests that no benefit may be realized from including Nef or
some Nef epitopes in such a vaccine. It also suggests that viral
escape from immune recognition is more likely to occur rapidly
for CTL epitopes of Nef. The notorious capability of HIV-1 to
escape from CTL recognition in Nef was supported by several
studies of HIV and SIV (17, 33, 35, 45, 46, 58). HIV-1 Nef is
believed to downmodulate the expression of MHC class I mol-
ecules, which in turn impairs CTL responses, resulting in an
inability to control virus replication (reviewed in references 2,
TABLE 3. Major HLA class I supertypes and their representation
in Botswana
HLA
supertypea
MHC class I HLA alleles; potential
alleles
Frequency
(total %)
in Botswana
A2 A*0201-0207, A*6802, A*6901 24
A3 A*0301, A*1101, A*3101, A*3301,
A*6801
8
B7 B*0702, B*3501-03, B*51, B*5301,
B*5401; B*0703-05, B*1508,
B*5501-02, B*5601-02, B*6701;
B*7801
12
B44 B*3701, B*4402-03, B60 (B*4001);
B61 (B*4006); B*18, B*4101,
B*4901, B*5001
20
A1 A*0101, A*2501, A*2601, A*2602,
A*3201; A*0102; A*2604,
A*3601, A*4301
14
A24 A*2301, A*2402-04, A*3001-03 37
B27 B*1401-02, B*1503, B*1509,
B*1510; B*1518, B*2701-08,
B*3801-02, B*3902-04, B*4801-
02, B*7301
22
B58 B*1516, B*1517, B*5701, B*5702,
B*58
21
B62 B*4601, B*52, B*1501 (B62),
B*1502 (B75), B*1513 (B77);
B*1301-02, B*1506, B*1512,
B*1514, B*1519, B*1521
3
a Sette and Sidney (62, 63).
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30, and 57). It is not clear whether Nef-mediated downmodu-
lation of HLA class I molecules plays a role in the observed
correlation between increased HIV-1C Nef-specific T-cell re-
sponses and elevated levels of plasma viral load.
Diversity in host genetics is likely to be manifested by as-
sorted virus-specific CTL responses for carriers of different
MHC class I HLA alleles or HLA supertypes. In the present
study the correlation between increasing HIV-1C Gag/Gag p24
immune responses and decreasing viral load within the HLA
supertypes A2, A24, B27, and B58 contrasted with the absence
of such a correlation for the HLA B44 supertype. This finding
demonstrates differences in virus-specific T-cell immune re-
sponses in subsets of the population according to expressed
HLA class I alleles or HLA supertypes. It is apparent that
carriers of the A2 supertype have a strong correlation between
T-cell responses and plasma viral load, whereas carriers of B44
supertype do not have such a correlation. In fact, many previ-
ous studies that have described a correlation between increas-
ing HIV-1-specific CTL responses and decreasing viral load for
HIV-1B have used HLA-A02–Gag epitope tetramer com-
plexes or Gag-specific CTL responses as markers of immune
response.
The genetic background of the population might be an im-
portant factor for vaccine efficacy, particularly when limited
epitope-specific vaccine designs are used. Kaslow et al. de-
scribed a predictive power for particular HLA class I alleles for
the outcome of vaccine trials, showing that individuals vacci-
nated with HLA-B*27 or HLA-B*57, HLA alleles associated
with slower disease progression, had better responses to an
ALVAC-HIV recombinant canarypox vaccine (32). The results
FIG. 3. Association between HIV-1C-specific T-cell responses and plasma viral load within the major HLA class I supertypes. Regression
curves represent results of unadjusted analysis. (A) Gag associations; (B) Gag p24 associations.
VOL. 77, 2003 HIV-1 SUBTYPE C INFECTION 887
 o
n
 April 1, 2016 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
of our study also point, although indirectly, to a potential
difference in immune responses among carriers of different
HLA supertypes. Assuming that differences in correlation pat-
terns are related to control of viremia, differences between
diverse MHC class I HLA supertypes should be taken into
account in vaccine design to elicit optimal CTL responses
within HLA supertypes, as well as to design vaccine efficacy
trials for participants that represent the population in which
such a vaccine would be used in the future. This information
could also be used in sieve analyses of efficacy trial data (20)
that assess whether the presence and number of HLA-re-
stricted epitopes in the infecting strain relative to the vaccine
strain(s) is associated with vaccine control of viral load.
Despite their usefulness for research analysis, the nine des-
ignated major HLA supertypes listed in Table 3 do not repre-
sent a final and comprehensive classification of MHC class I.
Not all HLA alleles were assigned to the major HLA super-
types (62, 63), i.e., HLA-A29, HLA-A34, HLA-A36, HLA-
A66, HLA-A74, HLA-B08, HLA-B42, and HLA-B45. Most of
those unclassified HLA supertypes are HLA specificities com-
mon in African countries. For example, HLA supertypes did
not include 18% of HLA-A and 23% of HLA-B antigen spec-
ificities that were found in the Botswana population (49). In
addition, placing all HLA-B58 alleles into one supertype prob-
ably needs to be further tested because of known structural and
binding differences between the HLA-B*5801 and HLA-
B*5802 alleles (22, 41). Since new HIV vaccine trials are being
designed for African populations where rates of HIV infection
are high, it would be important to facilitate the assignment of
missing alleles to the HLA supertypes.
In summary, we demonstrated different correlations be-
tween plasma viral load and T-cell immune responses in the
course of natural HIV-1C infection that included increasing
responses to Gag p24 and decreasing viral loads, as well as
increasing T-cell responses to Nef and increases in viral load.
Within the five major MHC class I HLA supertypes, a corre-
lation between reduced viral load and Gag p24-specific T-cell
responses within the A2, A24, B27, and B58 supertypes stood
out against no correlation within the HLA B44 supertype. We
suggest that the correlation within HIV-1C Gag p24 responses
makes the Gag p24 region an attractive vaccine candidate. In
contrast, the lack of such a correlation in Nef might suggest no
control of viremia. Identified differences in association be-
tween virus-specific T-cell responses and plasma viral load
should be considered in vaccine design and development, par-
ticularly as they relate to the populations of southern Africa
that are severely impacted by the epidemic of HIV-1C, which
has the highest rates of infection in the world (15, 16).
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